BD ex­ec Goater re­places Bin­iszkiewicz as chief at Sur­face On­col­o­gy; Arde­lyx bids farewell to CSO Cald­well

→ Sur­face On­col­o­gy has pro­mot­ed its BD chief to run the com­pa­ny. Jef­frey Goater is tak­ing the helm of the Cam­bridge, MA-based biotech, fo­cused on new drugs tar­get­ing CD47 and CD73 in the tu­mor mi­croen­vi­ron­ment. He’s re­plac­ing As­traZeneca vet Detlev Bin­iszkiewicz, who was re­cruit­ed a lit­tle less than three years ago. There’s no im­me­di­ate word on Bin­iszkiewicz’s next step.

→ Je­re­my Cald­well is trad­ing the CSO seat at Arde­lyx $ARDX for a CEO job at an undis­closed “ear­ly stage biotech start-up com­pa­ny based in San Diego,” the Fre­mont, CA-based com­pa­ny an­nounced to­day. His de­par­ture from the biotech, best known for IBS drug tena­panor, fol­lows a bumpy three-year ride that set tena­panor on course for an NDA sub­mis­sion de­spite some doubts along the way. No suc­ces­sor has been named just yet. “I be­lieve that tena­panor will play a crit­i­cal role in treat­ing both hy­per­phos­phatemia and IBS-C in the fu­ture. I’m proud of what we’ve dis­cov­ered with the RDX013 pro­gram, as it rep­re­sents an en­tire­ly new ap­proach to treat­ing hy­per­kalemia,” Cald­well said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER